METHOD AND APPARATUS FOR COMPUTER-AIDED DIAGNOSIS OF CANCER AND PRODUCT
    61.
    发明公开
    METHOD AND APPARATUS FOR COMPUTER-AIDED DIAGNOSIS OF CANCER AND PRODUCT 审中-公开
    方法和设备是治疗癌症和产品的计算机辅助诊断

    公开(公告)号:EP2147395A1

    公开(公告)日:2010-01-27

    申请号:EP08755735.1

    申请日:2008-05-16

    Abstract: Method and apparatus performing dynamic contrast-enhanced - magnetic resonance imaging on tissue to obtain a plurality of datasets of images. Principal component analysis is performed on each dataset to obtain a covariance matrix and its corresponding eigenvalues and eigenvectors and produce a common base of eigenvectors. The dominant eigenvectors that are not associated with instrumental and random noise, commonly the 2nd eigen-state and the 3rd eigenvectors, or the 1st and 2nd eigen vectors, are correlated with the physiological relevant parameters of the 3TP method to obtain a hybrid method. The fusion of the eigenvectors with the 3TP parameters is dictating a rotation of the two relevant eigenvectors to obtain new rotated eigenvectors that serve to calculate new projection coefficient maps of the rotated eigenvectors for the imaged tissue indicative of physiological relevant parameters reflecting wash-out and wash-in patterns that detect abnormal tissue and distinguishes between cancerous and benign tumors. Computer-readable medium containing program instructions for carrying out the above.

    USE OF AN ORGAN-SPECIFIC SELF-PATHOGEN FOR TREATMENT OF A NON-AUTOIMMUNE DISEASE OF SAID ORGAN
    64.
    发明公开
    USE OF AN ORGAN-SPECIFIC SELF-PATHOGEN FOR TREATMENT OF A NON-AUTOIMMUNE DISEASE OF SAID ORGAN 审中-公开
    特定器官甚至剂中的应用自身免疫疾病的不是有关机构的治疗

    公开(公告)号:EP1490086A2

    公开(公告)日:2004-12-29

    申请号:EP03744969.1

    申请日:2003-03-25

    CPC classification number: A61K39/0008 A61K38/1709 A61K2039/515 A61K2039/53

    Abstract: An agent selected from: (a) a pathogenic self-antigen associated with a T-cell-mediated specificautoimmune disease of an organ; (b) a peptide which sequence is comprised within the sequenceof (a); (c) a peptide obtained by modification of (b), by replacement of one or more amino acidresidues by different amino acid residues, said modified peptide still being capable of recognizingthe T-cell receptor recognized by the parent peptide but with less affinity; (d) a nucleotide sequenceencoding (a), (b), or (c) ; and (e) T cells activated by a pathogenic self-antigen of (a), a peptide of (b), or a modified peptide of (c), can be used for treatment of a non- autoimmunedisease, disorder or injury in said organ. For example, uveitogenic antigens or peptides thereof canbe used for treatment of a non-autoimmune disease, disorder or injury in the eye.

Patent Agency Ranking